|
Report Date : |
05.10.2012 |
IDENTIFICATION DETAILS
|
Name : |
JANSSEN KOREA
LTD. |
|
|
|
|
Registered Office : |
191, Hangangno 2-ga, Yongsan-gu, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
26.05.1983 |
|
|
|
|
Com. Reg. No.: |
120-81-11440 |
|
|
|
|
Legal Form : |
Co., Ltd by shares |
|
|
|
|
Line of Business : |
Manufacture of Finished Medicaments |
|
|
|
|
No. of Employees : |
463 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30th, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
|
Source
: CIA |
|
Company Name |
JANSSEN KOREA LTD. (Korean Company
Name : “(주)한국얀센”) |
|
Registered Address |
191, Hangangno 2-ga, Yongsan-gu, |
|
Building |
25th Fl., LS |
|
Zip Code |
140-702 |
|
Tel |
+82-2-2094-4500 |
|
Fax |
+82-2-2094-4570 |
|
E-mail |
|
|
Website |
|
|
Trading Address |
25th Fl., LS Yongsan Tower, 191, Hangangno
2-ga, Yongsan-gu, |
|
Tel |
+82-2-2094-4500 |
|
Fax |
+82-2-2094-4570 |
|
Other Address-Factory |
Hyangnam Pharmaceutical Industries
Complex, 905, Sangsin-ri, Hyangnam-eup, Hwaseong-si, |
|
Tel |
+82-31-353-5191 |
|
Fax |
+82-31-353-5192 |
|
Other Address-Nambu Branch |
5FL., Sungji Bldg., 1007-45,
Sadang-dong, Dongjak-gu, |
|
Tel |
+82-2-563-1403 |
|
Other Address-Bukbu Branch |
Rm.306, |
|
Tel |
+82-2-922-8827~8 |
|
Other Address-Suwon Branch |
28-2, Jeongja-dong, Bundang-gu, Seongnam-si, |
|
Tel |
+82-31-245-7191~3 |
|
Type |
Export/Import |
|
Industry |
Manufacture of Finished Medicaments |
|
Main Business |
Anodynia, Antipyretic, Digestant, Carcinostatis Substance, Medicine |
|
Established (mm/dd/yyyy) |
05/26/1983 |
The Subject owns
the premises of factory.
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Antihistamines or H1 blockers(51161600) |
|
Sell |
Cough and cold and antiallergy products(51161800) |
|
Sell |
Non narcotic analgesics and antipyretics(51142000) |
|
Sell |
Antiulcer and related gastrointestinal GI drugs(51171900) |
|
Sell |
Central nervous system drugs(51140000) |
|
Sell |
Antidepressants(51141600) |
|
Sell |
Non narcotic analgesics and antipyretics(51142000) |
|
Sell |
Antidiarrheals(51171700) |
|
Name |
Kim Yoon-Seob |
|
Address |
132-1103, 38, Mokdongseo-ro, Yangcheon-gu, |
|
Date of Birth |
07/20/1948 |
|
Title |
Co-President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
5,334,000,000 |
||||||||||||
|
Employees |
463 |
||||||||||||
|
Formation |
Co., Ltd by shares Foreign Direct Investment Corporation |
||||||||||||
|
Bank Details |
Shinhan Bank-Yeoksam Dong Branch Korea Exchange Bank |
||||||||||||
|
Corporate Registered No. |
110111-0350457 |
||||||||||||
|
Business Registered No. |
120-81-11440 |
||||||||||||
|
Permit & Licenses |
04/16/1999 ISO 14001 Int’l Trade No.: 437745 |
||||||||||||
|
Shareholder Position |
|
||||||||||||
|
Company History |
05/26/1983 Incorporated as the present
name, as a JV between YUHAN CORPORATION(110111-0014409) and JOHNSON &
JOHNSON(USA) 03/27/1985 Registered as a Foreign Direct
Investment Corporation 05/01/2008 Moved to the present HQ address from 12FL., Sungwon Bldg.,
141, Samseong-dong, Gangnam-gu, |
||||||||||||
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
Co-President & CEO |
Mr. |
Kim Yoon-Seob |
Male |
Korean |
03/31/2009 |
|
Co-President & CEO |
M/S. |
Kim Ok-Yeon |
Female |
Korean |
07/25/2012 |
|
Director |
Mr. |
Kim Hyung-Jin |
Male |
Korean |
07/25/2012 |
|
Director |
Mr. |
Lee Jung-Hee |
Male |
Korean |
03/31/2009 |
|
Director |
- |
Manisea Han |
- |
|
07/25/2012 |
|
Auditor |
Mr. |
Hwang Ju-Myung |
Male |
Korean |
03/08/1993 |
|
Auditor |
Mr. |
Jin Ki-Seob |
Male |
Korean |
03/30/2012 |
|
Supervisor |
Mr. |
Ha Yong-Jung |
Male |
Korean |
07/01/2011 |
Financials
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
231,978,387,182 |
130,693,277,231 |
24,897,436,342 |
|
|
2010 |
210,294,820,297 |
97,264,385,013 |
18,414,783,217 |
|
2009 |
203,148,864,816 |
93,105,308,866 |
21,641,811,233 |
|
2008 |
208,298,548,525 |
88,416,390,819 |
20,905,468,930 |
|
2007 |
190,067,192,178 |
85,986,170,930 |
19,493,694,916 |
|
2006 |
171,189,929,312 |
83,756,664,969 |
14,608,804,353 |
|
2005 |
153,718,737,387 |
86,204,046,262 |
7,164,224,447 |
Financial
Description
|
Authorized Capital(KRW) |
9,600,000,000 |
|
Paid-Up Capital(KRW) |
5,334,000,000 |
|
Total Issued Shares |
1,066,800 |
|
Unit : Korean Won |
As of 12/31/2011 |
As of 12/31/2010 |
As of 12/31/2009 |
|
Total Assets |
130,693,277,231 |
97,264,385,013 |
93,105,308,866 |
|
Current Assets |
110,418,142,972 |
80,375,270,629 |
76,618,418,676 |
|
-Quick Assets |
80,671,690,209 |
61,044,375,215 |
59,713,242,413 |
|
-Inventories |
29,746,452,763 |
19,330,895,414 |
16,905,176,263 |
|
Fixed Assets |
20,275,134,259 |
16,889,114,384 |
16,486,890,190 |
|
-Investment |
176,097,000 |
175,897,000 |
1,524,817,833 |
|
-Tangibles |
15,524,861,951 |
13,014,907,553 |
11,553,871,032 |
|
-Intangibles |
809,764,416 |
229,283,604 |
295,367,732 |
|
-Others |
3,764,410,892 |
3,469,026,227 |
3,112,833,593 |
|
Total Liabilities |
79,001,781,402 |
55,470,325,526 |
49,726,032,596 |
|
Current Liabilities |
76,085,192,595 |
52,770,088,674 |
47,408,880,765 |
|
Fixed Liabilities |
2,916,588,807 |
2,700,236,852 |
2,317,151,831 |
|
Capital Stock |
5,334,000,000 |
5,334,000,000 |
5,334,000,000 |
|
Capital Surplus |
|
|
|
|
Profit Surplus |
46,357,495,829 |
36,460,059,487 |
38,045,276,270 |
|
Capital Adjustment |
|
|
|
|
Total Equity |
51,691,495,829 |
41,794,059,487 |
43,379,276,270 |
|
Liab. & Shareholder’s Equity |
130,693,277,231 |
97,264,385,013 |
93,105,308,866 |
|
Current Liabilities |
76,085,192,595 |
52,770,088,674 |
47,408,880,765 |
|
Trade Payables |
1,226,416,355 |
470,941,547 |
246,260,892 |
|
Trade Payables to Related Companies |
12,722,572,388 |
6,345,471,090 |
3,646,256,841 |
|
Short-Term Borrowings |
35,200,000,000 |
20,300,000,000 |
22,800,000,000 |
|
Account Payables |
1,894,494,787 |
2,604,491,840 |
2,715,294,127 |
|
Account Payables to Related Companies |
763,467,601 |
3,062,944,393 |
523,209,451 |
|
Withholdings |
509,242,905 |
352,652,638 |
428,980,835 |
|
VAT Withhold |
2,060,913,953 |
1,751,028,477 |
1,602,304,670 |
|
Accrued Expenses |
14,099,854,990 |
12,139,181,655 |
10,232,205,552 |
|
Accrued Income Tax |
6,880,610,165 |
5,282,137,280 |
4,775,698,817 |
|
Provision for Refund |
653,186,577 |
418,945,300 |
399,808,000 |
|
Guarantee Deposit Withhold |
74,432,874 |
42,294,454 |
38,861,580 |
|
Fixed Liabilities |
2,916,588,807 |
2,700,236,852 |
2,317,151,831 |
|
Provision for Severance & Retirement |
16,104,585,900 |
17,102,139,427 |
15,520,130,634 |
|
Long-Term Account Payables |
2,900,625,923 |
2,656,896,530 |
2,317,151,831 |
|
Unit : Korean Won |
As of 12/31/2011 |
As of 12/31/2010 |
As of 12/31/2009 |
|
Sales |
231,978,387,182 |
210,294,820,297 |
203,148,864,816 |
|
Cost of Sold Goods |
123,716,523,582 |
112,540,281,882 |
102,447,335,358 |
|
Gross Profit |
108,261,863,600 |
97,754,538,415 |
100,701,529,458 |
|
Selling & Admin. Expenses |
71,208,271,290 |
68,377,582,664 |
70,177,022,337 |
|
Operating Income |
37,053,592,310 |
29,376,955,751 |
30,524,507,121 |
|
Non-Operating Income |
2,058,778,184 |
2,181,227,747 |
4,626,650,417 |
|
Non-Operating Expenses |
4,404,255,424 |
4,896,027,147 |
5,192,220,830 |
|
Income Before Taxes |
34,708,115,070 |
26,662,156,351 |
29,958,936,708 |
|
Income Taxes Expenses |
9,810,678,728 |
8,247,373,134 |
8,317,125,475 |
|
Net Income |
24,897,436,342 |
18,414,783,217 |
21,641,811,233 |
|
Unit : Korean Won |
As of 12/31/2011 |
As of 12/31/2010 |
As of 12/31/2009 |
|
Cash Flows from Operating |
5,243,458,823 |
22,229,632,373 |
19,907,079,394 |
|
-Net Income |
24,897,436,342 |
18,414,783,217 |
21,641,811,233 |
|
-Exp. without Cash Outflow |
6,821,961,791 |
6,743,453,342 |
6,044,315,255 |
|
-Revenue without Cash Inflows |
-54,149,150 |
-55,300,670 |
-81,329,142 |
|
-Changes in Asset/ & Liability |
-26,421,790,160 |
-2,873,303,516 |
-7,697,717,952 |
|
Cash Flows from Investing |
-5,041,425,236 |
-3,451,793,526 |
-1,042,626,900 |
|
-Cash Inflow from Investing |
195,698,707 |
49,422,874 |
2,955,478,840 |
|
-Cash Outflows for Investing |
-5,237,123,943 |
-3,501,216,400 |
-3,998,105,740 |
|
Cash Flows from Financing |
-100,000,000 |
-22,500,000,000 |
-15,700,000,000 |
|
-Cash Inflows from Financing |
35,200,000,000 |
20,300,000,000 |
15,800,000,000 |
|
-Cash Outflows from Financing |
-35,300,000,000 |
-42,800,000,000 |
-31,500,000,000 |
|
Increase/Decrease in Cash |
102,033,587 |
-3,722,161,153 |
3,164,452,494 |
|
Cash at the Beginning of Year |
12,441,167,971 |
16,163,329,124 |
12,998,876,630 |
|
Cash at the End of Year |
12,543,201,558 |
12,441,167,971 |
16,163,329,124 |
|
Main Products & Services |
Anodynia, Antipyretic, Digestant, Carcinostatis Substance, Medicine |
|
Competitors |
DONGA PHARMACEUTICAL CO.,
LTD.(110111-0017990) 252, YONGDU-DONG, DONGDAEMUN-GU, TEL:+82-2-920-8114 FAX:+82-2-924-2662 GREEN CROSS CORPORATION(110111-0109854) 303, BOJEONG-DONG, GIHEUNG-GU, YONGIN-SI, TEL:+82-31-260-9300 FAX:+82-31-260-9413 HANMI PHARM CO.,LTD.(134811-0003187) 893-5, HAJEO-RI, PALTAN-MYEON, HWASEONG-SI,
TEL:+82-31-356-3311 FAX:+82-31-356-5151 |
|
Affiliates |
JOHNSON & JOHNSON JANSSEN JANSSEN CILAG GMBH INT'L NCS ASIS PACIFIC JAN-CIL SOURCING J&J ( XIAN JANSSEN PHARMACEUTIC JAN-CIL |
|
Corporate Ownership |
JOHNSON & JOHNSON( |
The Subject deals
with the companies in
No.
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.51.97 |
|
|
1 |
Rs.83.67 |
|
Euro |
1 |
Rs.67.19 |
INFORMATION DETAILS
|
Report Prepared
by : |
PDT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.